Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimers Disease Neuroimaging Initiative
AJNR 36:653-660, Chow, N.,et al, 2015
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis
Ann Neurol 96:21-33, Gilligan,M.,et al, 2024
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome
Neurol 96:848-863, Katz, D.I.,et al, 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Mechanisms of Ischemic Stroke in Patients with Cancer
Ann Neurol 90:159-169, Navi, B.B.,et al, 2021
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 89:88-100, McKeith, I.G.,et al, 2017
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Paraneoplastic and Autoimmune Encephalitis
UpToDate, June, Dalmau, J.,et al, 2011
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
CSF and Plasma Biomarkers in Patients with Iatrogenic Cerebral Amyloid Angiopathy
Neurol 103:e209828, Pollaci,G.,et al, 2024
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
JAMA Neurol 76:1035-1048, Bridel, C.,et al, 2019
Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke
Stroke 50:2944-2947, Bang, O.Y.,et al, 2019
Diagnosis of Cerebral Amyloid Angiopathy
Stroke 49:491-497, Greenberg, S.M.,et al, 2018
D-dimer >2.785 �g/ml and multiple infarcts =3 vascular territories are two characteristics of identifying cancer-associated ischemic stroke patients
Neurol Res 40:948-954, Wang, J.,et al, 2018
Neurofilament as a Blood Marker for Diagnosis and Monitoring of Primary Progressive Aphasias
Neurol 88:961-969, Steinacker, P.,et al, 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
A Clinical Approach to Diagnosis of Autoimmune Encephalitis
Lancet Neurol 15:391-404, Graus, F.,et al, 2016
A Clinical Approach to the Diagnosis of Traumatic Encephalopathy Syndrome
JAMA Neurol 73:743-749, Reams, N.,et al, 2016
Polymyalgia Rheumatica and Giant Cell Arteritis
JAMA 315:2442-2458, Buttgereit, F.,et al, 2016
Cortical Superficial Siderosis
Neurol 87:1110-1117, Shams, S.,et al, 2016
Aphasic Variant of Alzheimer Disease
Neurol 87:1337-1343, Rogalski, E.,et al, 2016
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Anti-HMGCR Autoantibodies in European Patients with Autoimmune Necrotizing Myopathies
Medicine 93:150-157, Allenbach, Y.,et al, 2014
The Autosomal Recessive Cerebellar Ataxias
NEJM 366:636-646, Anheim,M.,et al, 2012
Infarct Volume is a Pivotal Biomarker After Inter-Arterial Stroke Therapy
Stroke 43:1323-1330, Yoo,A.J.,et al, 2012
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
JAMA 302:2565-2572, 2593, Lieb,W.,et al, 2009